Pharmacoeconomic evidence of bosentan for pulmonary arterial hypertension

References

• Hrometz S, Shields K. Role of ambrisentan in the management of pulmonary hypertension. Ann. Pharmacother.42, 1653–1658 (2008).
   PubMed Web of Science ®Google Scholar
• Rubin L, Badesch D, Barst R et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med.346, 896–903 (2002).
   PubMed Web of Science ®Google Scholar
• Galie N, Torbicki A, Barst R et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur. Heart J.25(24), 2243–2278 (2004).
   PubMed Web of Science ®Google Scholar
• Sitbon O, Badesch D, Channick R et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension. Chest124, 247–254 (2003).
   PubMed Web of Science ®Google Scholar
• D’Alonzo, Barst R, Ayres S et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann. Intern. Med.115, 343–349 (1991).
   PubMed Web of Science ®Google Scholar
• McLaughlin V, Sitbon O, Badesch D et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur. Respir. J.25, 244–249 (2005).
   PubMed Web of Science ®Google Scholar
• Hamilton N, Elliott C. Pulmonary hypertension – treatment options. Hosp. Pharm.13, 10–14 (2006).
   Google Scholar
• Garin MC, Clark L, Chumney EC, Simpson KN, Highland KB. Cost–utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model. Clin. Drug Investig.29(10), 635–646 (2009).
   PubMed Web of Science ®Google Scholar
• Christman BW, McPherson CD, Newman JH et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med.327(2), 70–75 (1992).
   PubMed Web of Science ®Google Scholar
• Tuder RM, Cool CD, Geraci MW et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med.159(6), 1925–1932 (1999).
   PubMed Web of Science ®Google Scholar
• Rubens C, Ewert R, Halank M et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest120(5), 1562–1569 (2001).
   PubMed Web of Science ®Google Scholar
• Abraham DJ, Vancheeswaran R, Dashwood MR et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am. J. Pathol.151(3), 831–841 (1997).
   PubMed Web of Science ®Google Scholar
• Chen YF, Jowett S, Barton P et al. Clinical and cost–effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health Technol. Assess.13(49), 1–320 (2009).
   PubMed Web of Science ®Google Scholar
• Wlodarczyk JH, Cleland LG, Keogh AM et al. Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing. Pharmacoeconomics24(9), 903–915 (2006).
   PubMed Web of Science ®Google Scholar
• Highland KB, Strange C, Mazur J, Simpson KN. Treatment of pulmonary arterial hypertension: a preliminary decision analysis. Chest124(6), 2087–2092 (2003).
   PubMed Web of Science ®Google Scholar
• Barst RJ, Langleben D, Badesch D et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J. Am. Coll. Cardiol.47(10), 2049–2056 (2006).
   PubMed Web of Science ®Google Scholar
• Wilkins MR, Paul GA, Strange JW et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. Am. J. Respir. Crit. Care Med.171(11), 1292–1297 (2005).
   PubMed Web of Science ®Google Scholar
• Simonneau G, Galie N, Rubin LJ et al. Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol.43(12 Suppl. S), 5S–12S (2004).
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N. Engl. J. Med.351(14), 1425–1436 (2004).
   PubMed Web of Science ®Google Scholar
• Barst RJ, Gibbs JS, Ghofrani HA et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J. Am. Coll. Cardiol.54(1 Suppl.), S78–S84 (2009).
   PubMed Web of Science ®Google Scholar
• Galie N, Hoeper MM, Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur. Heart J.30(20), 2493–2537 (2009).
   PubMed Web of Science ®Google Scholar
• Channick R, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet358, 1119–1123 (2001).
   PubMed Web of Science ®Google Scholar
• Galie N, Beghetti M, Gatzoulis M et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation114, 48–54 (2006).
   PubMed Web of Science ®Google Scholar
• Galie N, Rubin L, Hoeper M et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet371(9630), 2093–2100 (2008).
   PubMed Web of Science ®Google Scholar
• Mok MY, Tsang PL, Lam YM, Lo Y, Wong WS, Lau CS. Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension. Lupus16(4), 279–285 (2007).
   PubMed Web of Science ®Google Scholar
• Gatzoulis M, Beghetti M, Galie N. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int. J. Cardiol.127, 27–32 (2008).
   PubMed Web of Science ®Google Scholar
• Brun H, Thaulow E, Fredriksen PM, Holmstrom H. Treatment of patients with Eisenmenger’s syndrome with bosentan. Cardiol. Young17(3), 288–294 (2007).
   PubMed Web of Science ®Google Scholar
• Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study. Heart93(3), 350–354 (2007).
   PubMed Web of Science ®Google Scholar
• Sasayama S, Satoh T, Izumi T, Yoshida S, Kyotani S, Tahara N. Long-term trial of bosentan monotherapy for pulmonary arterial hypertension in Japanese patients. Curr. Med. Res. Opin.23(2), 395–400 (2007).
   PubMed Web of Science ®Google Scholar
• Sasayama S, Kunieda T, Tomoike H et al. Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension. Circ. J.69(2), 131–137 (2005).
   PubMed Web of Science ®Google Scholar
• Ibrahim R, Granton JT, Mehta S. An open-label, multicentre pilot study of bosentan in pulmonary arterial hypertension related to congenital heart disease. Can. Respir. J.13(8), 415–420 (2006).
   PubMedGoogle Scholar
• Benza RL, Rayburn BK, Tallaj JA et al. Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease. Chest129(4), 1009–1015 (2006).
   PubMed Web of Science ®Google Scholar
• Ahmadi-Simab K, Hellmich B, Gross WL. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease. Eur. J. Clin. Invest.36(Suppl. 3), 44–48 (2006).
   PubMed Web of Science ®Google Scholar
• Keogh A, Strange G, McNeil K et al. The bosentan patient registry: long-term survival in pulmonary arterial hypertension. Intern. Med. J.41(3), 227–234 (2011).
   PubMed Web of Science ®Google Scholar
• Ulrich S, Speich R, Domenighetti G et al. Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study). Swiss Med. Wkly137(41–42), 573–580 (2007).
   PubMed Web of Science ®Google Scholar
• Jing ZC, Strange G, Zhu XY et al. Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension. J. Heart Lung Transplant.29(2), 150–156 (2010).
   PubMed Web of Science ®Google Scholar
• Denton CP, Pope JE, Peter HH et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann. Rheum. Dis.67(9), 1222–1228 (2008).
   PubMed Web of Science ®Google Scholar
• Ibrahim R, Granton J, Mehta S. An open-label multicentre pilot study of bosentan in pulmonary arterial hypertension related to congenital heart disease. Can. Respir. J.13, 415–420 (2006).
   PubMedGoogle Scholar
• Keogh AM, McNeil KD, Wlodarczyk J, Gabbay E, Williams TJ. Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J. Heart Lung Transplant.26(2), 181–187 (2007).
   PubMed Web of Science ®Google Scholar
• Sitbon O, McLaughlin V, Badesch D et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax60, 1025–1030 (2005).
   PubMed Web of Science ®Google Scholar
• Strange G, Keogh A, Williams T, Wlodarczyk J, McNeil K, Gabbay E. Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life. Respirology13, 674–682 (2008).
   PubMed Web of Science ®Google Scholar
• Duffels MG, Vis JC, van Loon RL et al. Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down’s syndrome. Am. J. Cardiol.103(9), 1309–1315 (2009).
   PubMed Web of Science ®Google Scholar
• Provencher S, Sitbon O, Humbert M, Cabrol S, Jais X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur. Heart J.27, 589–595 (2006).
   PubMed Web of Science ®Google Scholar
• Stevenson MD, Macdonald FC, Langley J, Hunsche E, Akehurst R. The cost–effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO Functional Class III. Value Health12(8), 1100–1105 (2009).
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Mehta S. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis. Appl. Health Econ. Health Policy7(1), 43–59 (2009).
   PubMedGoogle Scholar
• Einarson TR, Granton JT, Vicente C, Walker J, Engel G, Iskedjian M. Cost–effectiveness of treprostinil versus epoprostenol in patients with pulmonary arterial hypertension: a Canadian analysis. Can. Respir. J.12(8), 419–425 (2005).
   PubMedGoogle Scholar
• Narine L, Hague LK, Walker JH et al. Cost-minimization analysis of treprostinil vs. epoprostenol as an alternate to oral therapy non-responders for the treatment of pulmonary arterial hypertension. Curr. Med. Res. Opin.21(12), 2007–2016 (2005).
   PubMed Web of Science ®Google Scholar
• Diller GP, Dimopoulos K, Kaya MG et al. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease. Heart93(8), 974–976 (2007).
   PubMed Web of Science ®Google Scholar
• Galie N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med.353(20), 2148–2157 (2005).
   PubMed Web of Science ®Google Scholar
• Williams MH, Das C, Handler CE et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart92(7), 926–932 (2006).
   PubMed Web of Science ®Google Scholar
• Oudiz RJ, Torres F, Frost A. ARIES-1: a placebo controlled, efficacy and safety study of ambrisentan in patients with pulmonary arterial hypertension [abstract]. Chest130(Suppl. 4), 121 (2006).
   Web of Science ®Google Scholar
• Barst RJ, Langleben D, Frost A et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.169(4), 441–447 (2004).
   PubMed Web of Science ®Google Scholar
• Olschewski H, Simonneau G, Galie N et al. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med.347(5), 322–329 (2002).
   PubMed Web of Science ®Google Scholar
• Olschewski H, Galie N, Kramer M. Ambrisentan improves exercise capacity and time to clinical worsening in patients with pulmonary arterial hypertension: results of the ARIES-2 study [abstract]. Presented at: 102nd International Conference of the American Thoracic Society. San Diego, CA, USA, 19–24 May 2006.
   Google Scholar
• Galie N, Olschewski H, Oudiz RJ et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation117(23), 3010–3019 (2008).
   PubMed Web of Science ®Google Scholar
• Archer SL, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N. Engl. J. Med.361(19), 1864–1871 (2009).
   PubMed Web of Science ®Google Scholar
• Kato I, Severson RK, Schwartz AG. Conditional median survival of patients with advanced carcinoma: surveillance, epidemiology, and end results data. Cancer92(8), 2211–2219 (2001).
   PubMed Web of Science ®Google Scholar
• Phung S, Strange G, Chung LP et al. Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. Intern. Med. J.39(10), 682–691 (2009).
   PubMed Web of Science ®Google Scholar
• Steele P, Strange G, Wlodarczyk J et al. Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy? BMC Cardiovasc. Disord.10, 9 (2010).
   PubMed Web of Science ®Google Scholar
• Keogh A, Strange G, Kotlyar E et al. Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report. Intern. Med. J.41(3), 235–244 (2011).
   PubMed Web of Science ®Google Scholar
• Souza R, Jardim C, Martins B et al. Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension. Curr. Med. Res. Opin.21(6), 907–911 (2005).
   PubMed Web of Science ®Google Scholar